CatalYm Presents Long-Term Phase 1/2a Data for Visugromab at ESMO 2025
CatalYm presented long-term Phase 1/2a data on visugromab at ESMO 2025, demonstrating sustained responses in patients with CPI-refractory tumors.
The median duration of response in non-squamous non-small cell lung cancer (nsqNSCLC) exceeded 32 months, 28 months in urothelial cancer, and 19 months in hepatocellular carcinoma (HCC).
Visugromab mitigates cachexia and re-sensitizes tumors to immunotherapy, showing favorable safety and tolerability in heavily pretreated patients.